

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/017998 A2

524,735
16 FEB 2005

- (51) International Patent Classification⁷: **A61K 47/00**, 9/107, 31/196
- (74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (21) International Application Number: **PCT/EP2003/009302**
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (22) International Filing Date: 21 August 2003 (21.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 02018772.0 22 August 2002 (22.08.2002) EP
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- (71) Applicant (*for all designated States except US*): **NOVARTIS CONSUMER HEALTH S.A.** [CH/CH]; Route de L'Etraz, CH-1260 Nyon (CH).
- Published:**
— without international search report and to be republished upon receipt of that report
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **STEIGER, Michel** [CH/CH]; Av. de la Perrausaz 90, CH-1814 La Tour-de-Peilz (CH).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **TOPICAL COMPOSITION**

(57) Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac sodium salt in unusually low amounts. Said compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

BEST AVAILABLE COPY

Topical Composition

The invention concerns topical formulations comprising the well-known and widely used non-steroidal anti-inflammatory drug (NSAID) diclofenac. It is one object of the present invention to provide an advantageous emulsion-gel specifically comprising the sodium salt of diclofenac, diclofenac Na. The latter represents the most simple, cheapest, most often used (taking into account oral and other routes of administration) and best studied derivative of diclofenac.

In US patent 4,917,886, a said emulsion-gel was disclosed already [see columns 2-3, composition B)]. However, the composition given there was an experimental one only and never commercialized. Its main purpose was to provide a direct comparison with the analogous crème composition A) comprising diclofenac Na and to demonstrate the superiority of emulsion-gels over ordinary crèmes. It had the following drawbacks: In order to obtain a sufficiently viscous emulsion-gel, especially in the presence of high amounts of lower alkanol (20% of isopropanol) and of an electrolyte (1% diclofenac Na), 1.2% of diethanolamine had to be used for neutralizing the gel-forming agent, polyacrylic acid (Carbopol 934 P).

However, nowadays the use of diethanolamine in topical formulations to be applied in humans is usually not recommended due to safety concerns about potential nitrosamine formation. It is therefore an object of the present invention to provide an emulsion-gel comprising diclofenac Na, which emulsion-gel can be obtained without neutralization with diethanolamine or other organic amines.

Moreover, a "true" emulsion-gel should be provided wherein diclofenac is fully dissolved (with no identifiable crystals of diclofenac being present in the formulation; see Test example 2 below) rather than partly suspended. This is crucial to guarantee a high, constant and reproducible permeation of diclofenac through the skin.

These aims have been achieved, surprisingly, by selecting specific components in specific amounts and so being able to neutralize the composition with ammonia, NaOH or KOH, in particular ammonia.

The invention is further characterized in that the beneficial topical formulations provided do include diclofenac, and diclofenac Na specifically, in unusually low amounts only (<0.5%, w/w). Said low dose formulations are particularly advantageous in the topical treatment of burns including sunburn. They are providing similar relief and healing as normal dose formulations (e.g. 1%) but lead to much lower exposure of the body to the active substance.

However, in order to provide a said low dose formulation, it is essential that the latter meets extraordinary standards with regard to stability, inter alia chemical stability of the active substance. Otherwise, the amount of active substance being present in the formulation over time may fall below the limits that have to be guaranteed to ensure proper pharmaceutical activity. It is therefore another object of the invention to provide a topical composition with such an extraordinary high stability profile that allows for formulating diclofenac in low doses (see Test example 1 below).

Therefore the invention relates to a pharmaceutical composition intended for topical use, which composition is in the form of an opaque emulsion-gel and which composition comprises

- (a) 0.02-0.4% (w/w) of diclofenac sodium salt,
- (b) at least 50% (w/w) of water,
- (c) 0-30% (w/w) of at least one C2-C4-alkanol,
- (d) 3-20% (w/w) of a glycol solvent selected from the group consisting of propylene glycol and polyethylene glycol (200-20000),
- (e) 0.2-3% (w/w) of at least one gelling agent selected from the group consisting of carbomers,
- (f) 2-8% (w/w) of at least one lipid forming the oily phase of the emulsion-gel,
- (g) 1-5% (w/w) of at least one non-ionic surfactant, and
- (h) a basic agent selected from the group consisting of ammonia, sodium hydroxide and potassium hydroxide to adjust the pH of the total composition to 6.5-8.

In one embodiment of the invention, said composition is devoid of any antifungal drug, e.g. devoid of terbinafine and topically acceptable salts thereof. In another embodiment of the invention, said composition is devoid of any further pharmaceutically active substance, that is to say, diclofenac sodium salt (a) is the only pharmaceutically active substance being present in that case.

All percentages given are percentages by weight (w/w), if not indicated otherwise.

Preferred are those compositions that comprise

- (a) 0.05-0.3% of diclofenac sodium salt,
- (b) 60-92% of water,
- (c) 0-25% of ethanol, isopropanol, or mixtures thereof,
- (d) 3-20% of propylene glycol,
- (e) 0.3-2% of at least one gelling agent selected from the group consisting of carbomers,
- (f) 3-7% of at least one lipid forming the fatty phase of the emulsion-gel,
- (g) 1-3% of at least one non-ionic surfactant, and
- (h) ammonia to adjust the pH of the total composition to 6.5-8.

In one embodiment of the invention, (c) is present in an amount of from 5 up to 25% and (d) is present in an amount of from 3 up to 7%, of the total composition. In another embodiment of the invention, (c) is present (or not, respectively) in an amount of from 0 up to 5%, in particular 0%, and (d) is present in an amount of from 3 up to 20% of the total composition.

In a further embodiment of the invention, (c) is present in an amount of from 0 up to 5% and (d) is present in an amount of from 3 up to 7% of the total composition. Said emulsion-gels have the additional advantage of being perceived by patients as very pleasant and non-sticky on the skin in consumer tests. Said advantage is especially pronounced, if said compositions, in addition, comprise as component (f) isopropyl myristate, and in particular a mixture of isopropyl myristate and C6-C12-alkanoic acid C12-C18-alkyl esters.

Preferably, diclofenac Na (a) is present in amount of from 0.05 up to 0.3% - especially of from 0.1 up to 0.25% - of the total composition.

Water (b) is preferably present in an amount of from 50 up to 92%, in particular of from 60 up to 90%, or of from 60 up to 80%, of the total composition.

Preferred as C2-C4-alkanols (c) are ethanol, isopropanol, or mixtures thereof; and in particular isopropanol. Preferably, (c) is present in an amount of from 0 up to 25%, in particular of from 0 up to 20%, of the total composition. In one embodiment, (c) is typically

present in an amount of from 5 up to 25%, and in particular of from 10 up to 20%, of the total composition. In another embodiment of the invention, (c) is present (or not, respectively) in an amount of from 0 up to 5% - preferably of from 0 up to 4%, more preferably of from 0 up to 3%, especially of from 0 up to 2%, and more especially of from 0 up to 1% - of the total composition.

Preferably, the glycol solvent (d) is propylene glycol. Propylene glycol is 1,2-propanediol. Alternatively, polyethylene glycol (200-20000) may be used as (d), preferably polyethylene glycol (200-1000). The glycol solvent (d) is preferably present in an amount of from 3.5 up to 20%, and in particular of from 4 up to 18%, of the total composition. In one embodiment, (d) is typically present in an amount of from 3 up to 7%, and in particular of from 3.5 up to 6%, of the total composition. In another embodiment of the invention, (d) is present in an amount of from 3 up to 20%, especially of from 4 up to 18%, of the total composition.

(e) Carbomers, in the context of the present invention, are defined as homo- or copolymers of acrylic acid that are cross-linked, e.g. with an allyl ether of pentaerythritol (allyl pentaerythritol) or an allyl ether of sucrose (allyl sucrose). Copolymers are formed e.g. with minor levels of long chain alkyl acrylate co-monomers. Homopolymers are preferred. Especially preferred are carbomers 980, 940, 981, 941, 974, 934 and 910. In particular preferred are the following products provided by Noveon, Inc, Cleveland, Ohio, USA (formerly B F Goodrich): Carbopol® 980 and Carbopol® 974, and analogous carbomer products from other suppliers. Preferably, (e) is present in an amount of from 0.3 up to 2%.

(f) Lipids form the oily phase of the emulsion-gels of the invention. They can be of a vegetable or animal nature, or partly or completely synthetic. There come into consideration lipids without ester linkages, e.g. hydrocarbons, fatty alcohols or fatty acids, and lipids having ester linkages, e.g. glycerides - i.e. fatty acid esters of glycerol -, or esters of fatty acids with C1-C36-alkanols. Hydrocarbons are e.g. paraffin or petroleum jelly. Fatty alcohols are e.g. decanol, dodecanol, tetradecanol, hexadecanol or octadecanol. Fatty acids are e.g. C6-C24-, especially C10-C18-, alkanolic acids, e.g. hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid or octadecanoic acid. Fatty acids further include unsaturated fatty acids, e.g. oleic acid or linoleic acid. Glycerides are e.g. olive oil, castor oil, sesame oil, it being possible for all said oils also to be hydrogenated; caprylic/capric acid triglyceride or glycerol mono-, di- and tri-esters with palmitic and/or

stearic acid. Esters of fatty acids with C1-C36-alkanols are e.g. beeswax, carnauba wax, cetyl palmitate, lanolin, isopropyl myristate, isopropyl stearate, oleic acid decyl ester, ethyl oleate, or C6-C12-alkanoic acid esters - especially caprylic/capric acid esters - with saturated fatty alcohols, especially C12-C18 saturated fatty alcohols.

- Preferred is a mixture of paraffin – especially liquid paraffin – and C6-C12-alkanoic acid C12-C18-alkyl esters – especially caprylic/capric acid esters with C12-C18 saturated fatty alcohols (coco-caprylate/caprate, e.g. Cetiol®LC) as well as a mixture of isopropyl myristate and C6-C12-alkanoic acid C12-C18-alkyl esters (as just characterized above). The lipid(s) (f) are preferably present in a total amount of 3-7, especially 4-6, % of the total composition. If a mixture of paraffin and coco-caprylate/caprate is used, the amount of paraffin is preferably 1.5-3%, especially 2-2.8%, and the amount of coco-caprylate/caprate is preferably 1.5-3%, especially 2-2.8%, of the total composition.

(g) A non-ionic surfactant is e.g. an ester of a fatty acid, especially a C8-C18 fatty acid, with monohydroxy or, preferably, polyhydroxy compounds, e.g. ethylene glycol, glycerol, anhydrosorbitol or pentaerythritol. Another important group of non-ionic surfactants is characterized by compounds having at least one active hydrogen, e.g. fatty alcohols - especially a C8-C18 fatty alcohol -, fatty acids - especially a C8-C18 fatty acid -, sorbitan fatty acid esters, C1-C18-alkylphenols or C8-C18-alkylamines, that all are poly(oxyethylated), preferably with from 2 up to 40 ethylene glycol or ethylene oxide units.

Examples for the above mentioned non-ionic surfactants are partial glycerin fatty acid esters, such as glycerin monostearate; partial fatty acid esters of sorbitan or polyoxyethylene sorbitan, such as sorbitan monolaurate or polyethylene glycol (5 to 20) sorbitan monostearate or monooleate; polyoxyethylene (3 to 40) fatty alcohol ethers, such as polyoxyethylene (3 to 12) lauryl ethers or polyoxyethylene (5 to 40) cetostearyl ethers; polyoxyethylene fatty acid esters, such as polyoxyethylene (8 to 100) stearate; polyoxyethylene C4-C12-alkylphenyl ethers, e.g. polyoxyethylene (nonyl or octyl)phenyl ethers; or polyoxyethylene C8-C18-alkylamines, e.g. polyoxyethylene oleylamine. Preferred are polyoxyethylene (10 to 30) fatty alcohol ethers, in particular polyoxyethylene (20) cetostearyl ether (e.g. Cetomacrogol 1000). The non-ionic surfactant (g) is preferably present in an amount of from 1.5 up to 2.5% of the total composition.

(h) Ammonia is preferably applied in the form of a concentrated aqueous solution thereof. To adjust the pH of the total composition to 6.5-8 – preferably 7-8 -, said concentrated aqueous solution of ammonia is e.g. present in an amount of 0.2-3% (w/w), especially 0.5-2% (w/w), of the total composition. Sodium hydroxide (NaOH) and potassium hydroxide (KOH) are e.g. applied as concentrated, e.g. 30%, aqueous solutions thereof.

The compositions of the inventions may optionally include further routine excipients known in the art, for example perfumes and antimicrobial preservatives, e.g. benzyl alcohol, benzalkonium chloride or parabens (= C1-C7-alkyl esters of 4-hydroxybenzoic acid, e.g. methyl 4-hydroxybenzoate).

In the experimental emulsion-gel "B)" disclosed in US patent 4,917,886, the addition of a chemical stabilizer (sodium sulphite) was necessary to provide a chemically stable formulation. In contrast thereto, the compositions of the present invention are chemically stable without a said stabilizer. In the absence of a stabilizer, e.g. the analytical work necessary to characterize the formulations and register them at the health authorities is simplified. Therefore, a further embodiment of the invention is characterized by the compositions disclosed hereinabove and hereinbefore, which compositions are devoid of a chemical stabilizer. Chemical stabilizers are e.g. antioxidants or chelating agents, e.g. EDTA.

The topical pharmaceutical compositions according to the invention are administered in a manner known per se. For example, they are applied e.g. once, twice, or three or four times daily to the affected portions of the skin.

The invention further relates to a method of treating inflammatory diseases which comprises topically administering to a mammal in need of such treatment a therapeutically effective amount of one of the topical pharmaceutical compositions as specified herein above and below.

The manufacture of the topical pharmaceutical preparations is effected in a manner known per se, for example as described in the examples below.

The following examples are intended to illustrate the invention.

Example 1: An emulsion gel comprising 0.1% of diclofenac Na

<u>Ingredients</u>	<u>Amount (kg/100kg)</u>
(a) diclofenac sodium salt	0.10
(b) purified water	76.57
(c) isopropanol	10.0
(d) propylene glycol	5.0
(e) Carbomer 980	0.7
(f') paraffin, liquid	2.5
(f'') coco-caprylate/caprate	2.5
(g) polyoxyethylene-20-cetostearyl ether	2.0
(h) ammonia, concentrated solution in water	<u>0.63</u>
	100.0

Manufacture: (a) is dissolved in (c), (d) and (h). Said solution is added to a mixture of (b) and (e). All remaining components – (f'), (f'') and (g) - are heated and slowly added to the former mixture. Upon mixing a homogeneous emulsion-gel is obtained.

Example 1a: An emulsion gel comprising 0.3% of diclofenac Na is obtained in an analogous manner to Example 1 but with using 0.30 of (a), 76.0 of (b), 0.9 of (e) and 0.8 of (h) instead.

Example 2: An emulsion gel comprising 0.1% of diclofenac Na [without (c)]

<u>Ingredients</u>	<u>Amount (kg/100kg)</u>
(a) diclofenac sodium salt	0.10
(b) purified water	74.9
(c) ---	----
(d) propylene glycol	15.0
(e) Carbomer 974P	1.0
(f') paraffin, liquid	2.5
(f'') coco-caprylate/caprate	2.5
(g) polyoxyethylene-20-cetostearyl ether	2.0
(h) 30% aqueous NaOH solution	1.5
benzyl alcohol (as preservative)	<u>0.5</u>
	100.0

Example 3: A sprayable emulsion gel (being more fluid but still opaque and homogeneous) comprising 0.1% of diclofenac Na [without (c)]

<u>Ingredients</u>	<u>Amount (kg/100kg)</u>
(a) diclofenac sodium salt	0.10
(b) purified water	86.68
(c) ---	----
(d) propylene glycol	5.0
(e) Carbomer 974P	0.3
(f') paraffin, liquid	2.5
(f'') coco-caprylate/caprate	2.5
(g) polyoxyethylene-20-cetostearyl ether	2.0
(h) 30% aqueous NaOH solution	0.42
benzyl alcohol (as preservative)	<u>0.5</u>
	100.0

The emulsion-gel is manufactured in a manner analogous to Example 1.

Test example 1: The stability of the emulsion gel of Example 1 is tested via an assay of diclofenac sodium. In doing so, the formulation is stored under various conditions (temperature/relative humidity) and for various storage times, and at the end the amount of diclofenac sodium still being present is determined. The results are as follows:

Storage time / Condition	25°C/60% r.h.	30°C/60% r.h.	40°C/75% r.h.
Start	101%		
3 months	101%	101%	100%
6 months	101%	101%	101%
9 months	100%	100%	

It is demonstrated that the active substance is completely stable even under demanding storage conditions for long periods of time.

Test example 2 (microscopical examination): The emulsion gel of Example 1 is examined under 100x magnification and scrutinized for the presence of any crystals of diclofenac

sodium. Absolutely no, not even tiny, crystals of diclofenac sodium are observed. One only sees the very fine droplets of the emulsion.

Claims

1. A pharmaceutical composition intended for topical use, which composition is in the form of an opaque emulsion-gel and which composition comprises

- (a) 0.02-0.4% (w/w) of diclofenac sodium salt,
 - (b) at least 50% (w/w) of water,
 - (c) 0-30% (w/w) of at least one C2-C4-alkanol,
 - (d) 3-20% (w/w) of a glycol solvent selected from the group consisting of propylene glycol and polyethylene glycol (200-20000),
 - (e) 0.2-3% (w/w) of at least one gelling agent selected from the group consisting of carbomers,
 - (f) 2-8% (w/w) of at least one lipid forming the oily phase of the emulsion-gel,
 - (g) 1-5% (w/w) of at least one non-ionic surfactant, and
 - (h) a basic agent selected from the group consisting of ammonia, sodium hydroxide and potassium hydroxide to adjust the pH of the total composition to 6.5-8;
- with the proviso that said composition is devoid of an antifungal drug.

2. A composition according to claim 1, which comprises

- (a) 0.05-0.3% of diclofenac sodium salt,
- (b) 60-92% of water,
- (c) 0-25% of ethanol, isopropanol, or mixtures thereof,
- (d) 3-20% of propylene glycol,
- (e) 0.3-2% of at least one gelling agent selected from the group consisting of carbomers,
- (f) 3-7% of at least one lipid forming the fatty phase of the emulsion-gel,
- (g) 1-3% of at least one non-ionic surfactant, and
- (h) ammonia to adjust the pH of the total composition to 6.5-8.

3. A pharmaceutical composition intended for topical use, which composition is in the form of an opaque emulsion-gel and which composition consists essentially of

- (a) 0.02-0.4% (w/w) of diclofenac sodium salt,
- (b) at least 50% (w/w) of water,
- (c) 0-30% (w/w) of at least one C2-C4-alkanol,
- (d) 3-20% (w/w) of a glycol solvent selected from the group consisting of propylene glycol and polyethylene glycol (200-20000),

- (e) 0.2-3% (w/w) of at least one gelling agent selected from the group consisting of carbomers,
- (f) 2-8% (w/w) of at least one lipid forming the oily phase of the emulsion-gel,
- (g) 1-5% (w/w) of at least one non-ionic surfactant, and
- (h) a basic agent selected from the group consisting of ammonia, sodium hydroxide and potassium hydroxide to adjust the pH of the total composition to 6.5-8.

4. A composition according to claim 1 or claim 3, wherein the polyethylene glycol (200-20000) usable as component (d) is polyethylene glycol (200-1000).
5. A composition according to any one of claims 1-4, which comprises (c) in an amount of from 5 up to 25% and (d) in an amount of from 3 up to 7% of the total composition.
6. A composition according to any one of claims 1-4, which comprises (c) in an amount of from 0 up to 5% and (d) in an amount of from 3 up to 20% of the total composition.
7. A composition according to any one of claims 1-4, which comprises (c) in an amount of from 0 up to 5% and (d) in an amount of from 3 up to 7% of the total composition.
8. A composition according to claim 6 or claim 7, which is devoid of the component (c).
9. A composition according to any one of claims 1-7, which comprises as C2-C4-alkanol (c) isopropanol.
10. A composition according to any one of claims 1-9, which comprises as gelling agent (e) carbomer 980, carbomer 940, carbomer 981, carbomer 941, carbomer 974, carbomer 934, carbomer 910, or a mixture of any of said carbomers.
11. A composition according to any one of claims 1-10, which comprises as lipid (f) either a mixture of paraffin and C6-C12-alkanoic acid C12-C18-alkyl esters, or a mixture of isopropyl myristate and C6-C12-alkanoic acid C12-C18-alkyl esters.
12. A composition according to any one of claims 5-7, which comprises as lipid (f) isopropyl myristate.

13. A composition according to any one of claims 1-12, which comprises as non-ionic surfactant (g) a polyoxyethylene (10 to 30) fatty alcohol ether.

14. A composition according to any one of claims 1-13, which is devoid of a chemical stabilizer.

(19) World Intellectual Property
Organization
International Bureau



16 FEB 2005



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/017998 A3

- (51) International Patent Classification⁷: **A61K 47/00**, 9/107, 31/196
- (21) International Application Number:
PCT/EP2003/009302
- (22) International Filing Date: 21 August 2003 (21.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
02018772.0 22 August 2002 (22.08.2002) EP
- (71) Applicant (for all designated States except US): **NOVARTIS CONSUMER HEALTH S.A.** [CH/CH]; Route de L'Etraz, CH-1260 Nyon (CH).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **STEIGER, Michel** [CH/CH]; Av. de la Perrausaz 90, CH-1814 La Tour-de-Peilz (CH).
- (74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
1 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TOPICAL EMULSION- GEL COMPOSITION COMPRISING DICLOFENAC SODIUM

(57) Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac sodium salt in unusually low amounts. Said compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

WO 2004/017998 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/09302

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/00 A61K9/107 A61K31/196

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 078648 A (LARNIER CATHERINE ;NOVARTIS CONSUMER HEALTH SA (CH); STEIGER MICHE) 10 October 2002 (2002-10-10)	3-5,9-14
P,Y	page 12; example 5	1,2
A	US 4 917 886 A (ASCHE HENNING ET AL) 17 April 1990 (1990-04-17) cited in the application	1-14
Y	page 2, line 60 -page 3, line 7	1,2
A	US 5 350 769 A (IKEDA YASUO ET AL) 27 September 1994 (1994-09-27) page 1, line 23 - line 38 page 2, line 6 - line 14 page 2, line 52 - line 67 examples 1,2	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 January 2004

Date of mailing of the international search report

04/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

VON EGGELKRAUT, S

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/09302

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02078648	A	10-10-2002	CA 2437789 A1	10-10-2002
			WO 02078648 A2	10-10-2002
US 4917886	A	17-04-1990	CH 655656 B	15-05-1986
			AT 381638 B	10-11-1986
			AT 354683 A	15-04-1986
			AU 567890 B2	10-12-1987
			AU 1994783 A	12-04-1984
			BE 897934 A1	06-04-1984
			CA 1228812 A1	03-11-1987
			DD 212897 A5	29-08-1984
			DE 3336047 A1	12-04-1984
			DK 460283 A ,B,	08-04-1984
			ES 8503944 A1	01-07-1985
			FI 833568 A ,B,	08-04-1984
			FR 2540726 A1	17-08-1984
			GB 2128087 A ,B	26-04-1984
			GR 79660 A1	31-10-1984
			HK 88590 A	02-11-1990
			HU 190168 B	28-08-1986
			IE 56023 B1	27-03-1991
			IL 69925 A	29-04-1988
			IT 1174791 B	01-07-1987
			JP 1852382 C	21-06-1994
			JP 5068444 B	29-09-1993
			JP 59089621 A	23-05-1984
			KR 8900493 B1	20-03-1989
			LU 85030 A1	10-05-1984
			NL 8303412 A ,B,	01-05-1984
			NO 833645 A	09-04-1984
			NZ 205882 A	12-11-1986
			PH 18646 A	23-08-1985
			PT 77459 A ,B	01-11-1983
			SE 455835 B	15-08-1988
			SE 8305316 A	08-04-1984
US 5350769	A	27-09-1994	WO 9207561 A1	14-05-1992
			CA 2058975 A1	01-05-1992

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.